Navigation Links
Amgen To Host Post American Society of Hematology (ASH) Summary Webcast
Date:12/10/2013

THOUSAND OAKS, Calif., Dec. 10, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will hold a post American Society of Hematology (ASH) summary webcast on Wednesday, Dec. 11, 2013, at 11 a.m. PST. Pablo Cagnoni, M.D., president of Onyx Pharmaceuticals, Inc. and Anthony C. Hooper, executive vice president of Global Commercial Operations at  Amgen, will participate in the call to discuss a brief summary of data presented at ASH. In addition, they will discuss a summary of feedback received from key opinion leaders and the steps Amgen is taking to develop Kyprolis® (carfilzomib) across all lines of therapy to address unmet needs in multiple myeloma patients.

Live audio of the investor call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. 

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Willow Grove, PA (PRWEB) August 28, 2014 ... talent, and create a culture that will allow individuals ... that are becoming increasingly important for employers looking to ... life science industries are embracing this trend, as the ... the fabric of a company, which will have real ...
(Date:8/28/2014)... 2014  Armetheon, Inc. ( www.armetheon.com ), a ... late-stage cardiovascular drug candidates, today announced that it ... of financing. The Series A round was co-led ... participation from investors that included Atheneos Capital and ... Larry Hsu , the founder of Impax Laboratories. ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Earlier this ... University in partnership with the U.S. Air Force ... biofuel. The results indicated that this type of fuel ... feedstock and will be important to America’s Eco friendly ... now has a mandate to become independent of foreign ...
(Date:8/27/2014)... August 27, 2014 Varian Medical Systems ... its current Salt Lake City manufacturing facility and allow ... Utah to ultimately create 1,000 new full time jobs ... , “Utah is home to hardworking people with immense ... credited with Varian’s success in the manufacturing of our ...
Breaking Biology Technology:Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3
... 15, 2011 This evening, Novo Nordisk awarded sponsorships ... support programs that educate people living with type 2 ... reduce the risk of long-term diabetes related complications. The ... program – a new initiative that aims to promote ...
... 15, 2011 Roka Bioscience announced today that the ... certification of the Listeria Detection Assay. This evaluation is ... (AOAC-RI) certification of methods used in the food safety ... laboratory and monitored by AOAC. The internal portion of ...
... /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP ... pharmaceutical and biotechnology research and development outsourcing company, ... leading Chinese pharmaceutical company, today announced that Shanghai ... and Hengrui have entered into a strategic partnership ...
Cached Biology Technology:Novo Nordisk and Atlanta Area Organizations Partner on Diabetes Education Programs 2Novo Nordisk and Atlanta Area Organizations Partner on Diabetes Education Programs 3Roka Bioscience Initiates External Trial for AOAC Certification 2ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development 2ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development 3
(Date:8/29/2014)... has been known about what genetic changes transform wild ... one of whom is a University of Montana assistant ... controlling the development of the brain and the nervous ... was published Aug. 28 in Science and ... at http://www.sciencemag.org/ ., The domestication of animals and ...
(Date:8/29/2014)... researchers explored the type and number of connections in ... plays on robustness in a study published in ... found that the assortativity signature contributes to a network,s ... that varying the out-out assortativity of TFN models has ... the other three types of assortativity," said Dov A. ...
(Date:8/29/2014)... as the prolific bloomer Emiliania huxleyi , can ... The finding contradicts the common view that E. ... scarce supplies of thiamine in the ocean to survive. ... the ocean," says CIFAR Senior Fellow Alexandra Worden ... with CIFAR fellows John Archibald (Dalhousie University), ...
Breaking Biology News(10 mins):New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Assortativity signatures of transcription factor networks contribute to robustness 2Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3
... Smart Search & Match,the leading provider of high-performance ... has joined the company as Product Marketing Manager. ... 15 years of product and marketing management,experience to ... many high-tech products and solutions worldwide. He has ...
... 2008 An international research team led by Tim ... the director of the School of Medicine,s Center for ... alternative splicing, the process by which single genes produce ... that curing the more than half of genetic diseases ...
... what they think may be a basic recipe for ... stem cells from essentially any mammal, including cows, pigs ... December 26th issue of the journal Cell , ... demonstrated to work in mice earlier this year, which ...
Cached Biology News:Case Western Reserve finds mechanism underlying alt. splicing of premessenger RNA into messenger RNA 2Case Western Reserve finds mechanism underlying alt. splicing of premessenger RNA into messenger RNA 3Recipe for capturing authentic embryonic stem cells may apply to any mammal, study suggests 2Recipe for capturing authentic embryonic stem cells may apply to any mammal, study suggests 3
... Storage: The kit is stable for 12 months ... contents of the kit cold. , ,Principle: ... silica-gel based membrane which selectively adsorbs up to ... specialized binding buffers. Nucleotides, oligos ( , ,Application: ...
The Econo gradient pump rack is a preassembled rack that is used to hold the components of the Econo gradient pump kits....
... Leu DAP FLISP Assay with FAM-Labeled ... nm) • Accurately measure serine protease ... permeabilization • B-Bridge's FLISP Kits utilize ... proteases (FLISPs) to measure chymotrypsin-like activity ...
... instrument is the cycler that revolutionized ... uniformity and swappable blocks ensure consistent ... This rugged machine is more than ... for new features and upgrades as ...
Biology Products: